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Antimicrobial peptideTyrocidine A, one of the ﬁrst antibiotics ever to be discovered, is a cyclic decapeptide that binds to membranes of
target bacteria, disrupting their integrity. It is active against a broad spectrum of Gram-positive organisms, and
has recently engendered interest as a potential scaffold for the development of new drugs to combat
antibiotic-resistant pathogens. We present here the X-ray crystal structure of tyrocidine A at a resolution of
0.95 Å. The structure reveals that tyrocidine forms an intimate and highly amphipathic homodimer made up of
four beta strands that associate into a single, highly curved antiparallel beta sheet. We used surface plasmon
resonance and potassium efﬂux assays to demonstrate that tyrocidine binds tightly to mimetics of bacterial
membranes with an apparent dissociation constant (KD) of 10 μM, and efﬁciently permeabilizes bacterial cells
at concentrations equal to and below the KD. Using variant forms of tyrocidine in which the ﬂuorescent probe
p-cyano-phenylalanine had been inserted on either the polar or apolar face of the molecule, we performed
ﬂuorescence quenching experiments, using both water-soluble and membrane-embedded quenchers. The
quenching results, together with the structure, strongly support a membrane association model in which the
convex, apolar face of tyrocidine's beta sheet is oriented toward the membrane interior, while the concave,
polar face is presented to the aqueous phase.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The development of antibiotics represents one of the crowning
achievements of 20th century medicine, and has vastly reduced the
morbidity and mortality caused by infection during the pre-antibiotic
era. However, antibiotic resistance has spread throughout most
human pathogens [1], while the number of new antibiotics in the drug
development pipeline has dwindled [2]. These developments have
precipitated a crisis in the treatment of bacterial infections, and threaten
to wipe out many of the advances made during the last century. This
situation has sparked interest in new classes of antibiotics, many of
which exploit different targets than those used by current drugs.
One interesting class of compounds under investigation includes the
cyclic natural products tyrocidine A, gramicidin S, and the streptocidins.
These compounds are produced as linear precursors by non-ribosomal
peptide synthesis in bacteria, which are then cyclized through the
action of thioesterase enzymes. TyrocidineAwas the ﬁrst suchmoleculey and Molecular Biology, Drexel
iladelphia, PA 19102, USA. Tel.:
uctural Biology, 205 route de
ersity of North Carolina, Chapelto be discovered, having been isolated from Bacillus brevis around 1940
by Dubos [3]; it is a major component of a mixture of antibacterial pep-
tides known as tyrothricin, the ﬁrst antibiotic to be successfully used for
the treatment of human disease [4,5]. At about the same time, gramici-
din S was shown to be produced by a different bacterial species
(Aneurinibacillus migulanus, originally classiﬁed as B. brevis), and subse-
quently proved to be of considerable medical utility during the Second
World War [6]. More recently, similar compounds (streptocidins)
have been found in species of Streptomyces [7,8]. All of these molecules
are cyclic decapeptides containing both D- and L-amino acids (Fig. 1).
As beﬁts the founding member of this class of antibiotics, many as-
pects of tyrocidine's biology and chemistry have been studied, including
its biosynthesis [9–11], physical behavior [12], mechanism [13–16], and
structure–activity relationships [17–24]. Tyrocidine A is bacteriocidal
toward a wide range of Gram-positive organisms, accumulating on
membranes of target bacteria and disrupting membrane integrity.
Because the target of the drug is the lipid bilayer, rather than a speciﬁc
macromolecule, microorganisms would need to introduce large-scale
changes in their cellular membranes in order to circumvent the drug's
action. The likelihood of this occurrence is extremely low [25], and
indeed no membrane alterations that confer resistance to tyrocidine A
or gramicidin S have been described. Other mechanisms of resistance
are possible, including increases in the thickness of barrier layers
[26–28] and complexation with neutralizing agents [29]; however,
such mechanisms do not appear to be widespread. Thus, the low
Fig. 1. Chemical structure of tyrocidine A. The numbering of residues is indicated in the
diagram by the italic numerals. Below the ﬁgure are shown the sequences of tyrocidine
A and the related decapeptide gramicidin S.
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simple structure, makes tyrocidine A and related molecules attractive
starting points for drug development. In any such development process,
selectivity is a critical issue, with drug candidates ideally being highly
selective for bacterialmembranes overmammalianmembranes. Tyroci-
dine A and gramicidin S are themselves poorly selective; they exhibit
considerable hemolytic activity in addition to their antimicrobial effects,
which severely limits their therapeutic utility. However, variants have
recently been discovered with vastly improved therapeutic indices,
displaying both increased antibacterial potency and reduced hemolytic
effects [21]. This suggests that it may be feasible to develop this scaffold
into a functional therapeutic.
The structure of tyrocidine A has long attracted the attention of
scientists; indeed, as long ago as 1955 Dorothy Crowfoot Hodgkin
wrote that this molecule's structure is “…of great interest and some
importance” [30]. The more recent realization that the tyrocidine scaf-
fold might provide a route to novel therapeutics has only increased in-
terest in high-resolution structural information for tyrocidine, as such
information should greatly facilitate the rational interpretation of struc-
ture–activity relationship data. Initial progress toward determining the
tyrocidine structure came from NMR analyses conducted in the 1980s,
which provided the ﬁrst pictures of tyrocidine [31–34]. However,
while these experiments were able to map most of the dihedral angles
for the peptide backbone, technical limitations led to ambiguities in
certain backbone dihedrals, and also precluded the determination of
the conformations of all side chains. Thus, while the NMR work has
provided a useful picture of the molecule's overall conﬁguration, many
details of the structure have remained unknown.
We present here the ﬁrst crystal structure for tyrocidine A, deter-
mined at a resolution of 0.95 Å. It reveals that the molecule forms an
amphipathic dimer, and suggests a model for how the antibiotic inter-
acts with bacterial membranes. We also present functional studies
that support this model of membrane interaction.
2. Methods
2.1. Materials
Lipids were purchased fromAvanti Polar Lipids (Alabaster, AL, USA).
Tyrocidine was synthesized by the method of Bu et al. [35] at Aves Labs
(Tigard, OR, USA) and puriﬁed by reverse-phase HPLC using a semi-preparative Ultrasphere 5 ODS C18 column (Hichrom, Berkshire, UK).
Tyrocidine was eluted with a gradient from 0.1% TFA/100% H2O to
0.1% TFA/95% acetonitrile; purity was approximately 98%, as estimated
from the chromatogram (Fig. S3, Supplementary data). Peak fractions
were pooled, lyophilized, and dissolved inmethanol at 30 mg/mL. Tyro-
cidine variants containing p-cyanophenylalanine were prepared in the
same manner. The crude p-cyanophenylalanine variants obtained
from the vendor were substantially less pure than the native tyrocidine,
complicating their puriﬁcation. Both puriﬁed variants showed a closely-
spaced doublet upon re-chromatographyon an analytical reverse-phase
column, the origin of which is not obvious (Fig. S3, Supplementary
data). The doublet was estimated to be 90% pure for [p-CN-Phe4]-tyro-
cidine and 88% pure for [p-CN-Phe7]-tyrocidine. Masses of the puriﬁed
antibiotics were veriﬁed by mass spectrometry (Drexel University
Department of Chemistry andWistar Institute Proteomics Facility, Phil-
adelphia, PA, USA; Figs. S4 & S5, Supplementary data), and the concen-
trations of the ﬁnal tyrocidine solutions were determined using amino
acid analysis (Keck Laboratory, Yale University, New Haven, CT, USA).
2.2. Crystallization
Sitting drops containing 10 μL of a tyrocidine solution (30 mg/mL in
methanol) were placed on siliconized glass posts (Hampton Research,
Aliso Viejo, CA, USA) and equilibrated at 18 °C with a reservoir solution
containing a 1:5 (v/v) mixture of 2,4-methylpentanediol (MPD) and
methanol. Crystals in the shape of triangular prisms were found after
approximately one month. Crystals were mounted on nylon loops,
dunked brieﬂy in neat MPD, and ﬂash-cooled in a stream of cold nitro-
gen gas prior to data collection.
2.3. Crystallographic structure determination and reﬁnement
A single crystal, maintained at 100 K, was used for data collection.
Data were measured at beamline X6A of the National Synchrotron
Light Source and processed using XDS [36]. Initial structure determi-
nation was carried out via direct methods using the SnB program
[37]. 78 of the antibiotic's 92 atoms were located after the initial
direct-methods phasing; the remaining atoms and solvent mole-
cules were placed in iterative rounds of reﬁnement and map inspec-
tion using Coot [38]. The structure was reﬁned using PHENIX v. 1.8.2-
1309 [39]. Anisotropic atomic displacement parameters were re-
ﬁned for all non-hydrogen atoms; hydrogen atoms were included
for the antibiotic molecule and one ordered MPD solvent molecule,
and were reﬁned using a riding model. No hydrogen atoms were
included for solvent water or methanol molecules. All of the
residues of the antibiotic fall within the most favored region of the
Ramachandran diagram. Three methanol molecules were found to
lie on or near crystallographic symmetry axes; the largest un-
modeled peaks in the ﬁnal difference Fourier maps are associated
with these methanol molecules, and likely reﬂect the difﬁculty of ad-
equately modeling disordered solvent lying near symmetry axes.
Representative 2Fo–Fc electron density for the ﬁnal model is
shown in Fig. S1 (Supplementary data). Data collection and reﬁne-
ment statistics are given in Table 1. Coordinates and structure factors
have been deposited with the Protein Data Bank (PDB ID: 4M6E).
Structure ﬁgures were made using MacPyMOL (Version 1.5.0.4
Schrödinger, LLC).
2.4. Liposome preparation
Lipids were dissolved in chloroform at 10 mg/mL and mixed in a
round-bottom ﬂask in appropriate proportions. The solvent was re-
moved in a rotary evaporator, thereby depositing a thin ﬁlm of lipid
on thewalls of the ﬂask. The sample was thenmoved to a−80° freezer,
after which any remaining traces of chloroformwere removed by over-
night lyophilization. The lipid ﬁlm was then treated with a buffer
Table 1
Data collection and reﬁnement statistics.
Data collection
Wavelength (Å) 0.8984
Spacegroup R32 (hexagonal setting)
Cell dimensions (Å) a = b = 33.39, c = 50.57
Resolution range (Å)a 19.0–0.95 (0.97–0.95)
No. observations 84,797 (1654)
No. unique reﬂections 6973 (454)
Completeness (%) 98.8 (88.5)
Mean multiplicity 12.2 (3.6)






Resolution range (Å) 19.0–0.95
Number of reﬂections used
Working set 6268
Test set 685
Number of antibiotic atoms 92




Estimated Wilson B value (Å2) 9.6





RMS deviations from ideal geometry
Bond distances (Å) 0.016
Bond angles (deg) 1.80
Rcryst/Rfree 0.134/0.141
Clashscore 0.0
a Values in parentheses refer to the highest resolution shell.
b Rmerge is calculated by the equation Rmerge= Σhkl∑ i|Ii(hkl)− 〈I(hkl)〉|/Σhkl∑ iIi(hkl),
where Ii(hkl) is the ith measurement.
c Rmeas (or redundancy-independent Rmerge) is calculated by the equation Rmeas ¼
∑hkl N= N−1ð Þ½ 
1=2∑i Ii hklð Þ− I hklð Þh ij j=Σhkl∑i Ii hklð Þ, where Ii(hkl) is the ith measure-
ment and N is the redundancy of each unique reﬂection hkl.
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cient hydration was achieved by spinning the ﬂask on a rotary evapora-
tor for 2 h (without vacuum), maintaining the temperature between 50
and 60 °C. The ﬂaskwas then vigorously vortexed for 5min, afterwhich
it was subjected to ﬁve freeze–thaw cycles using liquid nitrogen and a
37 °C water bath. The lipid suspension was then passed at least ten
times through an Avanti mini-extruder equipped with polycarbonate
membranes having 100 nm pores. The size of the resulting liposomes
were analyzed by dynamic light scattering using a DynaPro Titan instru-
ment (Wyatt Analytical Technologies, Santa Barbara, CA, USA), yielding
an estimated average diameter of 107 nm.
Lipid concentrations were determined by measurements of total
phosphorus, following a modiﬁcation of the method of Chen et al. [40]
as described by Avanti Polar Lipids (http://www.avantilipids.com).
Brieﬂy, about 0.1 μmol of each liposome preparation was added to the
bottom of a glass tube. 450 μL of 4.45 M sulfuric acid were added and
the tubes were heated to 210 °C for 25 min. The tubes were then
removed from the heating block and allowed to cool for 5 min before
adding 150 μL of 30% hydrogen peroxide with vortexing. The samples
were then heated above 210 °C for an additional 30 min, and then
cooled to room temperature. Next, to each tube was added 3.9 mL of
water, 0.5 mL of 2.5% ammonium molybdate(VI), and 0.5 mL of 10%
ascorbic acid, with mixing after each addition. Tubes were covered
with glass slides to prevent evaporation and heated at 100 °C for
7 min. After cooling to room temperature, the absorbance at 820 nm
was measured, using a sample containing no phosphate as the blank.
The standard curve was constructed using KH2PO4 in 50 mM HCl.2.5. Surface plasmon resonance
Binding analysiswasperformed at 25 °Cusing a Biacore 3000 instru-
ment (GE Life Sciences, Piscataway, NJ, USA). Liposomes were prepared
using dipalmitoyl-phosphatidylglycerol, stearamine, and cardiolipin in
a 5:1:1mole ratio, so as to approximately reﬂect themajor phospholipid
constituents of Staphyloccus aureus membranes [41]. Liposomes were
loaded onto the surface of an L1 chip to a density of approximately
1000 response units. Tyrocidine A was injected for a 2 min association
phase, followed by a 10 min dissociation phase. Surfaces were regener-
ated between each injection with CHAPS and the liposomes reloaded to
the same density. A blank surface served as the reference. The responses
at 100 s (averaged over ﬁve separate experiments) were plotted versus
tyrocidine A concentration and ﬁt to the four-parameter equation in
BiaEvaluation v4.1.1 to obtain the apparent equilibrium dissociation
constant (KD) and its estimated standard deviation.
2.6. Potassium efﬂux
Leakage of potassium ions from Micrococcus luteus cells (ATCC
49732) was measured at 25 °C as described [42], using the potassium-
sensitive dye PBFI (Molecular Probes). The EC50 value and its associated
standard deviation were estimated by ﬁtting a rectangular hyperbola to
the equilibrium change in ﬂuorescence as a function of antibiotic
concentration.
2.7. Fluorescence quenching experiments
Quenching experimentswere conducted using variant forms of tyro-
cidine in which a D-p-cyano-phenylalanine residue was incorporated at
position 4 (replacing the native D-Phe), or an L-p-cyano-phenylalanine
residue was incorporated at position 7 (replacing the native L-Tyr). For
all ﬂuorescence experiments a Jobin-Yvon Fluoromax-3 ﬂuorometer
was used, exciting at 240 nm and reading emission between 250 and
400 nm. All experiments were conducted at 37 °C. Both tyrocidine var-
iants were used at a concentration of 5 μM in 20 mM HEPES pH 7.0,
100 mM NaF, and 1 mM EDTA.
For experiments using soluble quenchers, liposomes were prepared
using a lipid composition of 75 mol% phosphatidylethanolamine,
20 mol% phosphatidylglycerol, and 5 mol% cardiolipin, and used at a
ﬁnal lipid concentration of 660 μM. Quenchingwas carried out by titrat-
ing with KI (concentration range 25 to 300 μM) or acrylamide (concen-
tration range 50 to 600 μM). Fluorescence intensities were corrected for
dilution effects.
For experiments using membrane-embedded quenchers, lipo-
somes were prepared using 75 mol% phosphatidylcholine, 20 mol%
phosphatidylglycerol, and 5 mol% cardiolipin. Four forms of
phosphatidylcholine (PC) were used: 1-palmitoyl-2-oleoyl-PC
(unquenched control), 1-palmitoyl-2-(6,7-dibromo)stearoyl-PC, 1-
palmitoyl-2-(9,10-dibromo)stearoyl-PC, and 1-palmitoyl-2-(11,12-
dibromo)stearoyl-PC. Liposomes were added to tyrocidine solutions
to give a ﬁnal calculated lipid concentration of 1 mM. Fluorescence
intensities measured from brominated liposome suspensions were
normalized by a factor that scaled the Rayleigh scattering of the
suspension to that of the control liposomes. Emission intensities




The crystallization of tyrocidine was reported by Magdoff-Fairchild
and White in the late 1970s [43], but no structure followed this report,
presumably because of the difﬁculties associated with phasing such a
“large small molecule” structure. In the intervening years, however,
Table 2




Phe3 amide Leu10 carbonyl 3.1
Asn5 amide Val8 carbonyl 2.9
Leu10 amide Phe3 carbonyl 3.0
Val8 amide Asn5 side chain 2.9
Intermolecular
D-Phe1 amide (molecule 1) Tyr7 carbonyl (molecule 2) 2.8
Orn9 amide (molecule 1) Orn9 carbonyl (molecule 2) 3.1
D-Phe1 amide (molecule 2) Tyr7 carbonyl (molecule 1) 2.8
Orn9 amide (molecule 2) Orn9 carbonyl (molecule 1) 3.1
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would make tyrocidine's structure determination feasible: bright
synchrotron beamlines have become common, improving our ability
to measure high-resolution data, and new dual-space direct methods
have been introduced that allow facile phase determination for even
large molecules [44,45]. In the hopes of applying these advances to
the structure determination of tyrocidine, we ﬁrst produced and
optimized well-ordered crystals, using the published crystallization
conditions of Magdoff-Fairchild andWhite as a starting point. As antic-
ipated, when analyzed usingmodern data collectionmethods (cryogen-
ic temperatures and an intense synchrotron radiation source), these
crystals diffracted strongly, providing data at a resolution in excess of
1 Å (Table 1). This high resolution data set proved highly suitable for
structure determination using direct phasing methods, and has yielded
a precise model for the antibiotic.
3.2. Tyrocidine structure
The tyrocidine molecule forms a two-stranded antiparallel beta
sheet, with the two strands connected at either end by tight turns
(Fig. 2). Residues Leu10, D-Phe1, Pro2, and Phe3 form a type II beta turn,
while at the other end of the molecule residues Asn5, Gln6, Tyr7, and
Val8 form a slightly distorted type I beta turn (backbone dihedral angles
are given in Table S1, Supplementary data). The two strands are con-
nected by three hydrogenbonds between backbone amide and carbonyl
groups (see Table 2). A fourth hydrogen bond is formed between the
backbone amide of Val8 and the side chain of Asn5. The strand–strand
associationwithin themonomer is also stabilized by hydrophobic inter-
actions between the side chains of D-Phe4, Val8, and Leu10.
The arrangement of L- and D-amino acids in the tyrocidine sequence
places more amino acid side chains on one face of the beta sheet thanFig. 2. The three-dimensional structure of tyrocidine A. (a) Stereoview of the tyrocidine A dime
trogen atoms blue. Inter-subunit hydrogen bonds are shown as black dotted lines, while intra-
glancing view of the convex (apolar) face of the dimer. (b) Side view of one tyrocidine monom
tyrocidine dimer. The color scheme has been chosen to highlight the amphipathic character
side chains are shown in blue, while hydrophilic side chains are shown in red. (d) Speculative
space-ﬁlling representation, in approximately the same orientation as seen in panel (c), with
level of the lipid head groups. In the antibiotic, carbon atoms are colored gray, oxygen atoms
while head group oxygen, nitrogen, and phosphorous atoms are colored red, blue, and orangethe other, giving rise to a pronounced curvature. Side chains oriented to-
ward the convex face of the molecule include those of Phe3, D-Phe4,
Asn5, Tyr7, Val8, and Leu10; in contrast, only the side chain of Orn9 is
found on the concave side of the sheet. The side chains of D-Phe1 and
Gln6 protrude from either end of the molecule in an equatorial
orientation.
The crystal asymmetric unit contains one tyrocidine monomer;
however, in the crystal lattice each tyrocidine monomer associates
with another monomer to form an intimate dimer, the two halves of
which are related by a two-fold axis of symmetry. The curved beta
sheets of each monomer pack edge-on, to form a continuous four-
stranded antiparallel sheet, with four backbone–backbone hydrogen
bonds joining the twomonomers (Table 2). In addition, the dimer is sta-
bilized by hydrophobic interactions between the side chains of Val8 of
onemonomer and Leu10 of the opposite monomer. Further stabilizationr. One monomer is colored cyan, and other yellow; oxygen atoms are colored red, and ni-
subunit hydrogen bonds are shown in magenta. Selected residues are labeled. Shown is a
er, showing the molecule's pronounced curvature. (c) Same view as in (b), showing the
of the dimer. For both monomers, the peptide backbone is shown in gray; hydrophobic
model for how the tyrocidine dimer interacts with membranes. The dimer is shown in a
the apolar convex face inserting into the bilayer, and the polar concave face sitting at the
red, and nitrogen atoms blue. Carbon tails of the membrane lipids are shown in yellow,
, respectively. Model lipid coordinates were taken from Pandit and Klauda [57].
Fig. 3. Interaction of tyrocidine A with lipid membranes. (a) Binding of tyrocidine A to
immobilized membranes, as monitored by surface plasmon resonance. (b) Perme-
abilization of bacterial membranes by tyrocidine A. Potassium release was monitored
from M. luteus cells using the potassium-sensitive dye PBFI. Varying concentrations of
the antibiotic were added at the time indicated by the arrow. The spike in ﬂuorescence
seen with 8 μM antibiotic likely represents transient local increases in [K+] resulting
from rapid catastrophic membrane depolarization. Inset shows the equilibrium change
in ﬂuorescence as a function of antibiotic concentration.
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rings of D-Phe1 and Tyr7 on opposing monomers.
The interaction between the two halves of the dimer is considerably
more extensive than any other crystal contacts. The surface area buried
in the dimer interface is 264 Å2, corresponding to 21% of themonomer's
total surface area. The fraction of fully buried atoms in the dimer inter-
face (fbu) is 0.31, consistent with this interface representing a speciﬁc
and biologically relevant recognition surface, rather than a fortuitous
crystal contact [46].
The tyrocidine dimer structure is distinctly amphipathic. All of the
amino acid side chains displayed on the convex face of dimer are hydro-
phobic, with the exception of the neutral polar Asn5, which is engaged
in a hydrogen bond with the backbone of the facing strand. In contrast,
the only side chain found on the concave face of the molecule is that of
the single charged residue, Orn9. In addition, backbone carbonyl oxy-
gens of three residues that are not involved in strand–strand hydrogen
bonds (D-Phe1, Asn5, and Gln6) point outward from the concave portion
of the molecular surface; further, the side chain of Gln6, which in the
crystal structure extends equatorially to engage in a lattice contact, is
well-positioned to turn toward the concave face aswell. Hence, the con-
cave face of the dimer adopts a polar character, while the opposite face
is strongly apolar.
3.3. Tyrocidine interaction with membranes
Tyrocidine is known to disrupt membranes [13], but the details of
the antibiotic–membrane interaction are lacking. To probe the nature
of this interaction,we used surface plasmon resonance to directly assess
tyrocidine binding to immobilized membranes. Using a lipid composi-
tion intended to mimic that of bacterial membranes, we found that ty-
rocidine bound readily and avidly to our immobilized membranes. The
kinetics of the interaction proved complex, andwere not adequately de-
scribed by simplemodels such as reversible monomer or dimer binding
or two-step binding processes. However, by using the conservative ap-
proach of plotting peak response values versus antibiotic concentration,
we obtained an estimate for the overall apparent dissociation constant
KD of 9.7 μM (see Fig. 3a). To provide context, we note that the range
of IC50 or minimum inhibitory concentration (MIC) values reported for
tyrocidine A extends from 1 to 25 μM [18,19,21–23].
Next, to conﬁrm that tyrocidine's membrane binding was linked to
its membrane disruption properties, we examined the antibiotic's abili-
ty to permeabilize bacterial membranes, using an efﬂux assay in which
drug-induced release of potassium ions from bacteria is measured with
a potassium-sensitive ﬂuorophore [42]. UsingM. luteus as a model bac-
terial organism, we saw clear dose-dependent membrane disruption
within the concentration range tested (0.8 to 8 μM), with an estimated
EC50 value of 2.4 ± 0.9 μM (see Fig. 3b). Hence, tyrocidine binds tightly
to membranes, and this binding correlates well with membrane
disruption.
3.4. Tyrocidine orientation on membranes
The amphipathic structure of the tyrocidine dimer suggests a model
for how themoleculemight interactwithmembranes. In thismodel, the
hydrophobic convex facewould insert into themembrane, facing the bi-
layer interior, while the polar concave face would be oriented toward
the aqueous phase (see Figs. 2d and 4a). To test thismodel, we prepared
two variants of tyrocidine A, withinwhich either a tyrosine or phenylal-
anine residue was replaced by the small intrinsic ﬂuorescent probe p-
cyanophenylalanine (p-CN-Phe) [47]. The two residues chosen for re-
placement were D-Phe4 and L-Tyr7, which were replaced by D- and L-
p-CN-Phe, respectively. The side chain of D-Phe4 extends from the center
of the convex, hydrophobic face of themolecule,while Tyr7 is at one end
of themonomer, with the side chain oriented toward the concave, polar
face of the molecule. Hence, in our simple model of membraneinteraction, D-Phe4 is predicted to be buried in the membrane interior,
while Tyr7 should be more solvent-exposed.
The solvent exposure of these two residues was ﬁrst probed using
hydrophilic quenchers of the p-CN-Phe ﬂuorescence. In the absence of
liposomes, the ﬂuorescence of the probe at both the 4- and 7-
positions was effectively quenched by both iodide and acrylamide
(see Fig. S2, Supplementary data). The addition of liposomes at a
100:1 mole ratio of lipid to tyrocidine provided signiﬁcant protection
for both the [p-CN-Phe4] and [p-CN-Phe7] variants of themolecule, con-
sistentwith tyrocidine binding to the liposomes. Stern–Vollmer analysis
was used to quantify the degree of protection afforded by membrane
binding (Fig. 4). For both iodide and acrylamide, larger quenching con-
stants were obtained when the p-CN-Phe probe was located at the 7-
position, rather than the 4-position (Table 3), indicating a greater de-
gree of protection for the probe located at the 4-position. Thus, the re-
sults with the soluble quenchers suggest that in the presence of
membranes, tyrocidine's 7-position is more solvent-exposed than the
4-position.
We then turned to quenchers located within the membrane bilayer.
We prepared liposomes containing phospholipids with dibrominated
Fig. 4. Probing tyrocidine's interaction with membranes using ﬂuorescence quenching. (a) Schematic model for the interaction of the tyrocidine dimer with membranes. The positions of
the two residues labeledwith the p-cyanophenylalanine probe are indicated. (b) Stern–Vollmer plots showing the quenching of labeled tyrocidine by iodide (left) and acrylamide (right),
in the presence of liposomes. Data points represent themean± standard deviation from 3–5 replicates. Solid lines correspond to [p-CN-Phe4]-tyrocidine and dashed lines to [p-CN-Phe7]-
tyrocidine. (c) Quenching of labeled tyrocidine by brominated phospholipids. Shown is the relative ﬂuorescence of the labeled tyrocidine, as compared to the level observed in
unbrominated POPC vesicles.
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6–7, 9–10, or 11–12 positions. We thenmeasured quenching of the two
ﬂuorescent tyrocidine variants for each type of liposome (Fig. 4). In each
case, we observed that [p-CN-Phe4]-tyrocidine was quenched moreTable 3







[p-CN-Phe4] 8.8 ± 0.6 3.9 ± 0.2
[p-CN-Phe7] 11.5 ± 0.7 5.6 ± 0.2
a Values represent the mean ± standard deviation of 3–5 measurements.efﬁciently than [p-CN-Phe7]-tyrocidine. Further, as the position of the
quencher was moved deeper into the interior of the bilayer, quenching
efﬁciency decreasedmonotonically for both the 4- and 7-labeled tyroci-
dine variants. These results indicate that the tyrocidine molecule is lo-
cated near the membrane surface, with its 7-position being farther
from the membrane interior than the 4-position.
4. Discussion
Tyrocidine was one of the ﬁrst antibiotics to be discovered, and in
the approximately sixty years since its discovery it has been studied ex-
tensively as a model for membrane-active natural products. Recently,
tyrocidine and related cyclic decapeptides have become the objects of
1205P.J. Loll et al. / Biochimica et Biophysica Acta 1838 (2014) 1199–1207renewed interest as the search for novel antibacterial agents has inten-
siﬁed [19,21,23]. Therefore, the structure of this molecule has been a
topic of great interest. Initial NMR experiments provided an overall
view of the molecule's conformation [31–34]; while the level of detail
obtainable from such analyses does not approach that of a high-
resolution crystal structure, the early NMR work allowed the inference
of backbone torsion angles that are in essential agreement with the
crystal structure and the prediction of three of the four intramolecular
hydrogen bonds that link the two antiparallel strands (the fourthhydro-
gen bond, involving the side chain of Asn5, was not correctly predicted
from the NMR work, which instead posited the carbonyl oxygen of
Asn5 as the hydrogen-bond acceptor). More recently, NMR restraints
have been incorporated into molecular dynamics simulations (NMR-
MD) to obtain models for tyrocidine [48]; this work suggests that a
hydrogen bond involving the carbonyl oxygen of Asn5 is substantially
less likely than the other three hydrogen bonds, in agreement with
the crystal structure. Backbone phi/psi angles predicted by the NMR-
MD method are also in good agreement with those seen in the crystal
structure, with the notable exception of D-Phe4. The NMR-MD phi/psi
values for this residue (~180°/180°) lie at the edge of the allowed region
in the Ramachandran plot, whereas the phi/psi values in the crystal
structure lie well within the preferred region for D-amino acids
(Table S1, Supplementary data). This difference has important structur-
al ramiﬁcations, as the NMR-MD models place the side chain of D-Phe4
facing the hydrophilic face of the molecule, whereas the crystal struc-
ture shows that it faces the opposite (hydrophobic) face. This leads
the NMR-MDwork to predict a substantially less amphipathic structure
than what is revealed by the crystal structure. Because of the ﬂipping of
D-Phe4, the NMR-MD models also fail to predict the marked curvature
that is seen in the crystal structure. A similar ﬂipped orientation was
assigned to D-Phe4 in another molecular modeling study [19]. Thus,
this crystal structure should prove a valuable addition to the ﬁeld, ex-
tending as it does the level of detail available from previous experimen-
tal structural work, as well as providing an objective standard against
which future computational studies can be benchmarked.
In addition to providing a detailed view of tyrocidine's molecular ar-
chitecture, this new structure also reveals a putative dimerizationmode
for the molecule. This dimerization has not been explicitly described in
previous structural studies, although the molecule's propensity for self-
association has been noted [12], and dimerization has been experimen-
tally observed in an aqueous solution usingmass spectrometry [48].We
speculate that the dimer seen in the crystal structuremay be physiolog-
ically relevant, based both upon the signiﬁcantmolecular surface buried
in the intimate dimer interface, and also upon the fact that the two
monomers in the dimer associate in such asway as to preserve and am-
plify the amphipathic nature of themonomers. Further, the structure of
the amphipathic dimer suggests a model for how tyrocidine interacts
with bacterial target membranes (Fig. 4), which is consistent with the
results of our ﬂuorescence quenching experiments.
The advent of this crystal structure presents the opportunity to
rationalize structure–activity data that have been accumulated for
tyrocidine. In particular, we sought to explain these data in terms
of both the molecule's three-dimensional structure and the
membrane interaction model it suggests. Many structure–activity
experiments have focused on speciﬁc positions in the molecule's
peptide sequence, with two of the most intensively studied sites
being D-Phe4 and Gln6. Substitutions at these positions signiﬁcantly
affect the therapeutic ratio (i.e., the ratio of the minimum hemolytic
concentration to the minimum concentration required to inhibit
bacterial growth) [18,21,24].
The structure reveals that D-Phe4 lies in the center of the hydropho-
bic face of the tyrocidine dimer (Fig. 2), and our membrane interaction
model predicts that the side chain of this residue penetrates into the hy-
drophobic core of the lipid bilayer. It is therefore not surprising that
many different hydrophobic D-amino acids can be substituted at this po-
sition with little effect on the molecule's antimicrobial activity [18,21].However, placing basic D-amino acids at this position sharply reduces
antibacterial potency [18,19,23], consistent with the structural predic-
tion that such substitutions should reduce amphipathicity and perturb
membrane interactions. The retention of residual activity by such vari-
ants may reﬂect the fact that basic side chains are typically long and
ﬂexible (e.g., Lys or Arg), and can therefore “snorkel” around the side
of the tyrocidine molecule to point toward the dimer's polar face [49].
In contrast, changing D-Phe4 to basic L-amino acids results in molecules
that retain antibiotic activity [18]. Such a D-to-L change would reverse
the orientation of the residue's side chain, causing it to point toward
theopposite side of the beta strand. Therefore, basic L-amino acids at po-
sition 4 would have their side chains oriented toward the molecule's
basic face, reinforcing rather than reducing the molecule's amphipathic
character. Interestingly, introducing N-methyl-D-Phe at position 4 does
not compromise antibacterial activity [18], even though, in general, in-
corporation of N-methylated amino acids is notwell tolerated by tyroci-
dine [23]. This general sensitivity to N-methylation likely reﬂects the
importance of inter-strand hydrogen bonding. However, the backbone
amide of residue 4 points outward from the edge of the dimer; it does
not hydrogen bond with any other strands, either within the molecule
or across the dimer interface, explainingwhymethylation at this partic-
ular position is tolerated.
Gln6 lies in one of the beta turns connecting the two strands of the
tyrocidine molecule. Gln6 extends in an equatorial direction, midway
between the molecule's polar and apolar faces (Fig. 2). In the crystal
structure, the residue's side chain accepts a hydrogen bond from its
own backbone amide nitrogen, and donates a second hydrogen bond
to a symmetry-related molecule in the lattice. Of fourteen different
L-amino acids that were substituted for Gln at this position, all were
found to improve antibacterial activity except Glu, which gave equiva-
lent activity to the parent compound [21]. A surprisingly diverse range
of residues are tolerated at this position, including large hydrophobes
such as leucine and tryptophan, uncharged polar amino acids such as
serine, and both acidic and basic residues. Our membrane interaction
model offers an explanation for how these disparate side chains can
all function at the same position, predicting that the turn containing
Gln6 will lie at the interface between the hydrophobic interior of the bi-
layer and the lipid head groups. This interfacial location allows different
types of side chains to be accommodated at position 6: polar side chains
placed at this position can turn toward the polar face of the molecule,
while hydrophobic side chains can turn in the opposite direction.
These adjustments can be accomplishedwith small changes in dihedral
angles and/or small changes in the overall orientation of the molecule.
Tyrocidine is closely related to gramicidin S, another cyclic
decapeptide produced by B. brevis, and it is instructive to compare the
structures of the two molecules. Crystal structures are available for
gramicidin S itself [50,51], as well as for several chemically modiﬁed
forms [52,53]. The most striking difference between tyrocidine and
any of the gramicidin S structures is the difference in curvature, with ty-
rocidine being much more highly curved than any of the gramicidin
structures (Fig. 5). This can be explained by the presence of two orni-
thine residues on the hydrophilic face of gramicidin S, as compared to
the single ornithine found on tyrocidine's polar face. The extra positive
charge and steric bulk contributed by the second ornithine is sufﬁcient
to prevent the two beta strands in gramicidin S from curling toward
their hydrophilic face, resulting in a rather ﬂat structure.
None of the gramicidin S crystal structures give any indication that
themolecule forms a symmetric dimer analogous to that seen in the ty-
rocidine crystal structure. However, in certain of the gramicidin
S crystal, forms inﬁnite extended sheets are observed,wherein onemol-
ecule hydrogen bonds with a two-fold related neighbor, which in turn
hydrogen bonds to another two-fold related neighbor, etc. [52]. This ex-
tended sheet formation is facilitated by the relatively ﬂat shape of the
gramicidin S monomer. In contrast, the more highly curved tyrocidine
molecule exhibits a strong degree of twist within the two beta strands
of the monomer; the two-fold related molecule twists in the opposite
Fig. 5. Comparison of tyrocidine A and gramicidin S. A side view of both antibiotics is shown, emphasizing the difference in curvature.
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dimer, linking these dimers into extended sheets is not feasible.
The signiﬁcance of any higher order structure formation for
antibiotic activity is not clear. It appears likely that tyrocidine will
dimerize on target membranes, but it is much less clear that grami-
cidin S does so as well; yet both molecules effectively permeabilize
membranes. Hence, it is possible that dimerization is not required
for tyrocidine's permeabilization activity, but rather evolved to
serve some other function. For example, tyrocidine binds and inacti-
vates the linear peptide toxin gramicidin A [13], and interacts with
RNA polymerase to inhibit initiation of transcription [54]; perhaps
dimerization facilitates one of these roles. Alternatively, if assembly
of higher order structures upon target membranes is required for
permeabilization, perhaps gramicidin S accomplishes this by
forming extended sheet structures, rather than the symmetric di-
mers favored by tyrocidine.
Interestingly, despite their structural differences, tyrocidine and
gramicidin S appear to share similar modes of membrane interaction.
Both experimental [55] and computational [56] studies agree that the
amphipathic gramicidin S molecule localizes to the bilayer/water inter-
face, with its two beta strands lying in the plane of the membrane and
its hydrophobic side facing the bilayer core, in amanner essentially sim-
ilar to what we propose for tyrocidine.5. Conclusions
The atomic resolution structure of tyrocidine has now become
known, revealing the precise details of the molecule's conformation
and demonstrating the formation of an intimate and highly amphipath-
ic dimer. This structure, together with supporting functional experi-
ments, suggests a model for membrane interaction in which the dimer
sits at the membrane–water interface, with the apolar convex face
pointing downward into the membrane interior, and the polar concave
face pointing upward toward the aqueous phase.Acknowledgements
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